Analyst Price Targets — GDRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 6:08 pm | Michael Cherny | Leerink Partners | $3.00 | $2.02 | StreetInsider | GoodRx Holdings Inc. (GDRX) PT Lowered to $3 at Leerink Partners |
| January 22, 2026 6:00 am | Glen Santangelo | Jefferies | $2.75 | $2.58 | StreetInsider | Jefferies Downgrades GoodRx Holdings Inc. (GDRX) to Hold |
| December 18, 2025 12:54 pm | — | Morgan Stanley | $4.00 | $2.78 | TheFly | GoodRx price target lowered to $4 from $5 at Morgan Stanley |
| December 8, 2025 9:14 pm | — | Barclays | $3.00 | $2.72 | TheFly | GoodRx initiated with an Underweight at Barclays |
| August 11, 2025 11:01 am | George Hill | Deutsche Bank | $6.00 | $3.47 | TheFly | GoodRx price target lowered to $6 from $8 at Deutsche Bank |
| June 10, 2024 5:32 am | Craig Hettenbach | Morgan Stanley | $9.50 | $8.55 | TheFly | GoodRx price target raised to $9.50 from $7 at Morgan Stanley |
| May 23, 2024 1:50 am | Mark Mahaney | RBC Capital | $10.00 | $7.20 | StreetInsider | RBC Capital Upgrades GoodRx Holdings Inc. (GDRX) to Outperform |
| May 16, 2024 2:46 pm | Stephanie Davis | Barclays | $9.00 | $8.06 | StreetInsider | Barclays Reiterates Overweight Rating on GoodRx Holdings Inc. (GDRX) |
| May 16, 2024 5:57 am | Aaron Kessler | Raymond James | $10.00 | $7.27 | StreetInsider | Raymond James Upgrades GoodRx Holdings Inc. (GDRX) to Outperform |
| April 10, 2024 12:10 pm | Scott Schoenhaus | BOCOM International Holdings Company | $9.00 | $6.92 | Benzinga | GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings |
Latest News for GDRX
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific…
• GoodRx Holdings shares are advancing steadily. What's driving GDRX shares up?
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers…
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available…
Nutex Health (NASDAQ: NUTX - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations. Profitability This table compares Nutex Health and GoodRx's
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GDRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.